Key result
Walking regimen plus L-arginine improves walking distance by ~40 m in PAH.
Why the study?
Does a prescribed 12-week mostly home-based walking regimen plus L-arginine supplementation improve 6-minute walk distance, peak aerobic capacity, and quality of life in clinically stable patients with pulmonary arterial hypertension?
Does a prescribed 12-week mostly home-based walking regimen plus L-arginine supplementation improve 6-minute walk distance, peak aerobic capacity, and quality of life in clinically stable patients with pulmonary arterial hypertension?
This proof-of-concept pilot study demonstrates that an accessible, mostly home-based walking regimen combined with L-arginine supplementation safely improves exercise capacity (6MWT and VO2max) and quality of life in clinically stable PAH patients without requiring hospital-based supervision.
Answers are grounded in this paper and cite their sources.
May support home-based regimens in stable PAH; hypothesis-generating and requires randomized confirmation before practice change.
Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital‐based programs limit patient accessibility to this important intervention. Our proof‐of‐concept study aimed to provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n = 7) or III (n = 5) and in stable condition for ≥ 3 months were enrolled. Patients performed home‐ and fitness‐center‐ based walking at 65–75% heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L‐arginine supplementation (6000 mg/day) was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6‐min walk testing (6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF‐36) were performed at baseline and 12 weeks. Eleven patients completed the study (72 session adherence rate = 96 ± 3%). Objective improvement was demonstrated by the 6MWT distance (increased by 40 ± 13 m, P = 0.01), VO2max (increased by 2 ± 0.7 mL/kg/min, P = 0.02), time‐to‐VO2max (increased by 2.5 ± 0.6 min, P = 0.001), VO2 at anaerobic threshold (increased by 1.3 ± 0.5 mL/kg/min, P = 0.04), HR recovery (reduced by 68 ± 23% in slope, P = 0.01), and SF‐36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 ± 34% and 74 ± 34%, respectively, P < 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide levels remained stable, suggesting safety of the intervention. This proof‐of‐concept study indicates that a simple walking regimen with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function and QoL measures. Further investigation in a randomized controlled trial is warranted.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2017) studied Pulmonary arterial hypertension (PAH) (n=12). Prescribed home- and fitness-center-based walking regimen plus L-arginine supplementation vs. Baseline (pre-intervention; each patient served as her own control) was evaluated on Change from baseline in 6-minute walk test (6MWT) distance at 12 weeks (MD 40 m, p=0.01). A 12-week walking regimen plus L-arginine supplementation increased walking distance by 40 m and VO2max by 1.8 mL/kg/min in patients with PAH.
Synapse has enriched 10 related papers. Consider them for comparative context: